Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
Conditions:   Gastric Cancer;   Gastroesophageal Junction Cancer;   HER2-positive Gastric Cancer
Interventions:   Combination Product: margetuximab plus INCMGA00012;   Combination Product: Margetuximab plus INCMGA00012 plus chemo;   Combination Product: Margetuximab plus MGD013 plus chemo;   Combination Product: Margetuximab plus chemo;   Combination Product: Trastuzumab plus chemo
Sponsors:   MacroGenics;   Zai Lab (Shanghai) Co., Ltd.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 2, 2019 / by / in
Comments